Summary A new antitumour agent is described, which has been shown to induce a G2/M block in murine leukaemia cells in vitro. In addition this agent has been shown to be equally toxic toward parental and daunorubicin-resistant P388 cells in vitro. These resistant cells are highly cross-resistant to the established antimitotic agents vincristine and vinblastine. Drug accumulation studies in cells have shown that whereas resistance in this cell line is associated with decreased drug accumulation in the case of daunorubicin, vincristine and vinblastine, this effect is much less pronounced for amphethinile.
One of the most clinically useful groups of anticancer drugs are the microtubule assembly inhibitors belonging to the vinca alkaloid group. These drugs continue to be extracted and purified from the Catharanthus species as it is still not feasible to synthesise them by any commercially viable procedure. A simple synthetic analogue may therefore provide an alternative spindle poison, with sufficiently different mode of action, cell permeability and other physicochemical characteristics to be a useful addition to the clinic.
An agent, (2-amino-3-cyano-5-(phenylthio)-indole, ICI 134154, Figure 1 ) has been identified which appears to affect the microtubular control of mitosis. The compound, named amphethinile, which is currently undergoing clinical trials, has now been studied in more detail to determine if these earlier observations can be substantiated and if so whether the action of the drug closely resembles or differs significantly from that of the vinca alkaloids. It would be interesting to determine if this synthetic compound shows cross resistance to a cell line which exhibits pleiotropic drug response characteristics of some naturally occurring antitumour agents, including the vinca alkaloids (Blick et al., 1986; Dano et al., 1983; Gerlach et al., 1986) .
In addition, following perclinical formulation and toxicology, the pharmacokinetic characteristics of this agent have been determined in male mice in preparation for the clinical studies which will be described elsewhere. (Table  II) show reduced drug accumulation in the resistant cell line. However the ratio of drug accumulated in the parental cell line compared to the resistant is greater for daunorubicin (2.72-fold), vinblastine (3.72-fold) and vincristine (2.25-fold) From the flow cytometric analysis (Figure 2 ), amphethinile can be seen to cause a G2/M phase arrest in cell cycle progression. This is similar to that observed for the vinca alkaloids (McGown et al., 1984) .
Materials and methods

Drugs
Animal toxicity Preclinical toxicology was undertaken using the clinically formulated drug. The formulation consisted of 10 g amphethinile and 100g Solutol HS15 diluted to 200ml with 70% ethanolic citrate buffer at pH 6.0. The resulting drug concentration was 50mg ml -1. The highest level of Solutol alone, 18 mg/mouse, was shown to be non-toxic under these administration conditions.
The LD10 values were 137mgkg-1 (411mgm-2, i.v.), 152mgkg-1 (456mgm 2, i.p.) and -50mgkg 1 (150mgm2, i.p.) daily for 5 days, four successive weekly administrations. Germ cell necrosis was seen in most mice, a minimal necrosis was seen in glandular, squamous or submucosal areas of the stomach and of the crypt epithelium cells in the small intestine. However these latter changes were only seen after the highest dose levels. In a similar way, some bone marrow lesions were seen in the highest, near lethal doses only. Tables III and IV . At this stage, the total level of the drug (>90%) was measured, i.e., chloroform extractable, in order to compare directly with the clinical data to follow. At this stage it is not possible to indicate whether the slow release of drug from the protein-bound complex may or may not contribute to the effectiveness of the drug in vivo. This must be the subject of a separate investigation.
The drug showed a biphasic decline in serum concentration, the half life (beta phase) remaining constant with increasing dose. Doubling of the dose resulted in a three fold increase in the area under the curve (AUC). The AUC value at the LD10 value was 313,ugl-1 h-1. Cross resistance between the anthracycline antibiotics and the vinca alkaloids has been described in many cells types (Dano et al., 1983; Tsuruo, 1983; Stark, 1986) . This multidrug or pleiotropic drug resistance exhibited by these cell lines, has been shown to be associated with decreased cellular drug retention. The precise mechanism by which this occurs is not known but is a protein mediated (Blick et al., 1986; Gerlach et al., 1985; Stark, 1986) , energy dependent process (Dano et al., 1983) . It is likely that the anthracyclines and vinca alkaloids share a common or related efflux pathway. The lack of cross-resistance observed towards amphethinile, together with the decreased drug accumulation differential of 33% observed between the parental and resistant cell lines is evidence that amphethinile is either not a substrate or is a poor substrate for this drug efflux process. This difference between the vinca alkaloids and amphethinile may prove useful in the treatment of tumours which have developed resistance to vinca alkaloids. In view of the clinical potential of this agent, it was submitted to preclinical formulation and toxicological studies. It was shown to be 100-fold less toxic than vincristine. Pharmacokinetic studies further indicated that there was a beta half-life of -100 min in mice, which was independent of dose administered, which suggests that there is no saturable metabolic process involved. In view of the current interest in comparing AUC measurements, (Collins et al., 1986) , the value observed in serum following i.v. bolus administration, indicated that -313 Mg 1 -I h-I was obtained at the LD10 levels. This may be a useful indicator for appropriate dose escalation in phase I trials of this agent.
